Uropathy Treatment Market

Uropathy Treatment Market

Uropathy Treatment Market Forecasts to 2030 - Global Analysis By Type (Obstructive Uropathy, Functional Uropathy, Inflammatory Uropathy, Congenital Uropathy and Urological Cancers), Treatment Type, Diagnosis, End User and By Geography

4.7 (32 reviews)
4.7 (32 reviews)
Published: 2024 ID: SMRC25098

This report covers the impact of COVID-19 on this global market

According to Stratistics MRC, the Global Uropathy Treatment Market is accounted for $4.4 billion in 2023 and is expected to reach $6.6 billion by 2030 growing at a CAGR of 6.0% during the forecast period. Uropathy refers to a broad range of conditions affecting the urinary tract, including the kidneys, ureters, bladder, and urethra. Treatment for uropathy depends on the specific underlying cause and severity of the condition. Innovation extends beyond procedures. Early diagnosis through advanced imaging techniques like 3D prostate MRI empowers timely intervention. Personalized medicine tailors treatment plans based on individual genetic and molecular profiles, paving the way for more effective and targeted therapies.

According to a study published in Advances in Urology, Kidney stone disease is an increasing urological disorder of human health which is affecting about 15% of the world population and it affects all age groups but occurs more frequently in men than in women within the age of 20-49 years. 

Market Dynamics: 


Rising incidence of urological conditions

As the prevalence of disorders such as urinary tract infections, kidney stones, and prostate issues continues to rise, there is a heightened demand for effective and innovative treatments. This surge in patient numbers not only underscores the urgent need for advanced therapeutic solutions but also propels research and development efforts within the Uropathy Treatment sector. Thus the increased focus on urological health, fuelled by the rise in awareness and education, further amplifies the market's expansion, creating opportunities for advancements in diagnostics, pharmaceuticals, and medical interventions to cater to the escalating healthcare needs associated with urological conditions.


Shortage of qualified healthcare professionals

Uropathy, as an unconventional treatment, requires specialized knowledge and expertise for proper administration and monitoring. The scarcity of qualified professionals including urologists and healthcare providers with specific training in uropathy, results in delayed diagnosis, inadequate treatment, and compromised patient care. Moreover, the shortage contributes to increased workloads for existing healthcare professionals, potentially leading to burnout and decreased quality of care impeding the market growth.


Increased awareness of urological health and the availability of various treatment options

As individuals become more informed about urological disorders and their potential consequences, there is a growing emphasis on preventive measures and early detection. This trend has driven a surge in patient screenings, consultations, and proactive healthcare seeking behaviours, positively influencing the demand for uropathy treatments. This not only caters to individual preferences but also promotes personalized treatment plans, enhancing overall patient satisfaction and compliance. The combined effect of heightened awareness and treatment options contributes to the growth of the market


Lack of standardized protocols and guidelines 

The lack of established norms for uropathy treatments leads to variability in procedures, dosages, and application methods, raising concerns about safety, efficacy, and reproducibility. This inconsistency creates uncertainty among healthcare professionals, making them hesitant to integrate uropathy into routine clinical practices. Patients may be hesitant to explore uropathy treatments due to the perceived lack of standardization and assurance of safety. Developing and promoting standardized protocols are essential for overcoming these obstacles and fostering confidence in the market.

Covid-19 Impact

The unprecedented strain on healthcare systems and resources, coupled with lockdowns and travel restrictions, has led to delays in urological procedures and reduced patient visits for non-emergent conditions. Many healthcare facilities have diverted their focus and resources toward managing the surge in COVID-19 cases, affecting the delivery of uropathy treatments. Moreover, the economic repercussions of the pandemic have influenced patient priorities, with some individuals opting to postpone elective urological treatments due to financial uncertainties hampering the market growth.

The obstructive uropathy segment is expected to be the largest during the forecast period

The obstructive uropathy segment is estimated to have a lucrative growth, as patients with obstructive uropathy may experience impaired urinary flow, leading to various complications such as kidney damage and infections. The market for uropathy treatment may see an increased demand for interventions addressing obstructive uropathy, including surgical procedures, catheterization, and pharmacological treatments. Additionally, the market may witness a surge in research and development efforts focused on addressing the underlying causes of obstructive uropathy, including the development of targeted therapies which encourage in the market growth.

The urinalysis segment is expected to have the highest CAGR during the forecast period

The urinalysis segment is anticipated to witness the highest CAGR growth during the forecast period, because the analysis of urine samples allows healthcare professionals to detect various abnormalities, such as infections, kidney diseases, and metabolic disorders, influencing the course of uropathy treatments. Precise urinalysis results aid in diagnosing the root cause of urological conditions, enabling personalized and effective treatment plans. Furthermore, urinalysis contributes to the monitoring and assessment of treatment efficacy, allowing adjustments based on patient responses boosting the markets growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the prevalence of urological conditions like kidney stones, prostate enlargement, and urinary incontinence increases in this region are fuelling demand for treatment options. Moreover minimally invasive surgeries, robotic-assisted procedures, and advanced imaging technologies are transforming urological care, offering precise and effective treatments with faster recovery times are driving the growth of the market in this region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to Conditions like kidney stones, urinary tract infections (UTIs), and prostate cancer are becoming increasingly common in North America. This is due to factors like aging population, sedentary lifestyles, and rising obesity rates. Moreover, the field of urology has seen significant advancements in recent years, with the development of minimally invasive procedures, robotic surgery, and personalized medicine approaches. These advancements are leading to improved patient outcomes and shorter recovery times thus encouraging the growth of the market.

Key players in the market

Some of the key players in the Uropathy Treatment Market include Abbott, Novartis AG, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., Eli Lilly and Company, Ionis Pharmaceuticals, Inc., Pfizer, Inc., Merck & Co. Inc., GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Bayer AG, Antares Pharma, Allergan, AstraZeneca, Cook Medical, Sanofi, Olympus Corporation, Teleflex Incorporated and Argon Medical Devices, Inc  

Key Developments:

In January 2024, Abbott announced the first global procedures have been conducted using the company's new Volt™ Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib).

In January 2024, Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis. FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond 

In October 2023, Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers. Novartis is committed to providing a consistent, reliable supply of Pluvicto and making this important medicine readily available to patients.

Types Covered:
• Obstructive Uropathy
• Functional Uropathy
• Inflammatory Uropathy
• Congenital Uropathy
• Urological Cancers
Treatment Types Covered:
• Drug Therapy
• Surgery Procedures
• Lifestyle Modification

Diagnosis Covered:
• Urinalysis
• Blood Tests
• Imaging Tests

End Users Covered:
• Hospitals & Clinics
• Ambulatory Surgical Centre
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary          
2 Preface           
 2.1 Abstract          
 2.2 Stake Holders         
 2.3 Research Scope         
 2.4 Research Methodology        
  2.4.1 Data Mining        
  2.4.2 Data Analysis        
  2.4.3 Data Validation        
  2.4.4 Research Approach        
 2.5 Research Sources         
  2.5.1 Primary Research Sources       
  2.5.2 Secondary Research Sources       
  2.5.3 Assumptions        
3 Market Trend Analysis         
 3.1 Introduction         
 3.2 Drivers          
 3.3 Restraints         
 3.4 Opportunities         
 3.5 Threats          
 3.6 End User Analysis         
 3.7 Emerging Markets         
 3.8 Impact of Covid-19         
4 Porters Five Force Analysis         
 4.1 Bargaining power of suppliers        
 4.2 Bargaining power of buyers        
 4.3 Threat of substitutes        
 4.4 Threat of new entrants        
 4.5 Competitive rivalry         
5 Global Uropathy Treatment Market, By Type       
 5.1 Introduction         
 5.2 Obstructive Uropathy        
 5.3 Functional Uropathy        
 5.4 Inflammatory Uropathy        
 5.5 Congenital Uropathy        
 5.6 Urological Cancers         
6 Global Uropathy Treatment Market, By Treatment Type      
 6.1 Introduction         
 6.2 Drug Therapy         
  6.2.1 Antibiotics        
  6.2.2 Pain Relievers        
  6.2.3 Alpha-Blockers or Alpha-Reductase Inhibitors     
  6.3.4 Hormone Therapy        
 6.3 Surgery Procedures         
  6.3.1 Cystoscopy        
  6.3.2 Lithotripsy        
  6.3.3 Ureteroscopy        
  6.3.4 Stenting         
 6.4 Lifestyle Modification        
7 Global Uropathy Treatment Market, By Diagnosis       
 7.1 Introduction         
 7.2 Urinalysis         
 7.3 Blood Tests         
 7.4 Imaging Tests                
8 Global Uropathy Treatment Market, By End User       
 8.1 Introduction         
 8.2 Hospitals & Clinics         
 8.3 Ambulatory Surgical Centre        
 8.4 Other End Users         
9 Global Uropathy Treatment Market, By Geography       
 9.1 Introduction         
 9.2 North America         
  9.2.1 US         
  9.2.2 Canada         
  9.2.3 Mexico         
 9.3 Europe          
  9.3.1 Germany         
  9.3.2 UK         
  9.3.3 Italy         
  9.3.4 France         
  9.3.5 Spain         
  9.3.6 Rest of Europe        
 9.4 Asia Pacific         
  9.4.1 Japan         
  9.4.2 China         
  9.4.3 India         
  9.4.4 Australia         
  9.4.5 New Zealand        
  9.4.6 South Korea        
  9.4.7 Rest of Asia Pacific        
 9.5 South America         
  9.5.1 Argentina        
  9.5.2 Brazil         
  9.5.3 Chile         
  9.5.4 Rest of South America       
 9.6 Middle East & Africa        
  9.6.1 Saudi Arabia        
  9.6.2 UAE         
  9.6.3 Qatar         
  9.6.4 South Africa        
  9.6.5 Rest of Middle East & Africa       
10 Key Developments          
 10.1 Agreements, Partnerships, Collaborations and Joint Ventures     
 10.2 Acquisitions & Mergers        
 10.3 New Product Launch        
 10.4 Expansions         
 10.5 Other Key Strategies        
11 Company Profiling          
 11.1 Abbott          
 11.2 Novartis AG         
 11.3 Bristol-Myers Squibb Co.        
 11.4 F. Hoffmann-La Roche Ltd.        
 11.5 Genentech, Inc.         
 11.6 Eli Lilly and Company        
 11.7 Ionis Pharmaceuticals, Inc.        
 11.8 Pfizer, Inc.         
 11.9 Merck & Co. Inc.         
 11.10 GlaxoSmithKline         
 11.11 Teva Pharmaceutical Industries Ltd.       
 11.12 Bayer AG          
 11.13 Antares Pharma         
 11.14 Allergan          
 11.15 AstraZeneca         
 11.16 Cook Medical         
 11.17 Sanofi          
 11.18 Olympus Corporation        
 11.19 Teleflex Incorporated        
 11.20 Argon Medical Devices, Inc        
List of Tables           
1 Global Uropathy Treatment Market Outlook, By Region (2021-2030) ($MN)    
2 Global Uropathy Treatment Market Outlook, By Type (2021-2030) ($MN)     
3 Global Uropathy Treatment Market Outlook, By Obstructive Uropathy (2021-2030) ($MN)   
4 Global Uropathy Treatment Market Outlook, By Functional Uropathy (2021-2030) ($MN)   
5 Global Uropathy Treatment Market Outlook, By Inflammatory Uropathy (2021-2030) ($MN)   
6 Global Uropathy Treatment Market Outlook, By Congenital Uropathy (2021-2030) ($MN)   
7 Global Uropathy Treatment Market Outlook, By Urological Cancers (2021-2030) ($MN)   
8 Global Uropathy Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)    
9 Global Uropathy Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)    
10 Global Uropathy Treatment Market Outlook, By Antibiotics (2021-2030) ($MN)    
11 Global Uropathy Treatment Market Outlook, By Pain Relievers (2021-2030) ($MN)    
12 Global Uropathy Treatment Market Outlook, By Alpha-Blockers or Alpha-Reductase Inhibitors (2021-2030) ($MN) 
13 Global Uropathy Treatment Market Outlook, By Hormone Therapy (2021-2030) ($MN)   
14 Global Uropathy Treatment Market Outlook, By Surgery Procedures (2021-2030) ($MN)   
15 Global Uropathy Treatment Market Outlook, By Cystoscopy (2021-2030) ($MN)    
16 Global Uropathy Treatment Market Outlook, By Lithotripsy (2021-2030) ($MN)    
17 Global Uropathy Treatment Market Outlook, By Ureteroscopy (2021-2030) ($MN)    
18 Global Uropathy Treatment Market Outlook, By Stenting (2021-2030) ($MN)    
19 Global Uropathy Treatment Market Outlook, By Lifestyle Modification (2021-2030) ($MN)   
20 Global Uropathy Treatment Market Outlook, By Diagnosis (2021-2030) ($MN)    
21 Global Uropathy Treatment Market Outlook, By Urinalysis (2021-2030) ($MN)    
22 Global Uropathy Treatment Market Outlook, By Blood Tests (2021-2030) ($MN)    
23 Global Uropathy Treatment Market Outlook, By Imaging Tests (2021-2030) ($MN)       
24 Global Uropathy Treatment Market Outlook, By End User (2021-2030) ($MN)    
25 Global Uropathy Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)   
26 Global Uropathy Treatment Market Outlook, By Ambulatory Surgical Centre (2021-2030) ($MN)  
27 Global Uropathy Treatment Market Outlook, By Other End Users (2021-2030) ($MN)   
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

List of Figures


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.

Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.

For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.


Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.